Results of ZD0473 in platinum-pretreated ovarian cancer: Analysis according to platinum free interval

European Journal of Cancer

Volumn 38, Issue SUPPL. 8, 2002, Pages

  Gore, M E ^a   Atkinson, R J ^b   Thomas, H ^c   Cure, H ^d   Rischin, D ^e   Beale, P ^f   Bougnoux, P ^g   Dirix, L ^h   Smit, W M ⁱ  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c Royal Surrey Hospital   (United Kingdom)

^d Jean Perrin Centre   (France)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g CHU BRETONNEAU   (France)

^h Oncologisch Centrum   (Belgium)

ⁱ MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Monotherapy; Ovarian cancer; Platinum resistance; ZD0473

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM(II); AMMINEDICHLORO(2-METHYLPYRIDINE)PLATINUM(II); PLATINUM COMPLEX;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CHEMOTHERAPY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MONOTHERAPY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; DRUG RESISTANCE; HEMATOLOGIC DISEASE; MIDDLE AGED; MULTICENTER STUDY; OVARY TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 0036980475     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)80014-4     Document Type: Article

References (26)

1. Conte PF, Cianci C, Tanganelli L, Gadducci A. Ovarian cancer: optimal therapy in relapsed disease. Ann Oncol 2000, 11, 145-150.
2. Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 1998, 77, 366-373.
3. Akiyama S-I, Chen Z-S, Sumizawa T, Furukawa T. Resistance to cisplatin. Anticancer Drug Design 1999, 8, 143-151.
4. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990, 36, 207-211.
5. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991, 9, 389-393.
6. Ozols RF. Update of the NCCN ovarian cancer guidelines. Oncology 1997, 11, 95-105.
7. Piccart MJ, Lamb H, Vermorken JB. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol 2001, 12, 1195-1203.
8. Medina-Gundrum L, Gomez L, Cerna C, et al. ZD0473 exhibits marked in vitro antitumour activity in human tumour specimens. Eur J Cancer 2001, 37, 454 (abstr).
9. Raynaud FI, Boxall FE, Goddard PM, et al. cis-Amminedichloro(2- methylpyridine)platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res 1997, 3, 2063-2074.
10. nd International Lung Cancer Conference, Hawaii, July 18-21, 2001.
11. Kelland L, Judson I, Koehler M, Stephens T, Roberts D. Preclinical and clinical overview of the novel platinum complex, ZD0473 (cis-amminedichloro [2-methylpyridine] platinum [II]). Lung Cancer 2000, 70, 227 (abstr).
12. Gore ME, Atkinson RJ, Thomas H, et al. A phase II trial of ZD0473 in platinum-pretreated ovarian cancer. Eur J Cancer 2002, In Press.
13. Canetta R, Bragman K, Smaldone L, Rozencweig M. Carboplatin: current status and future prospects. Cancer Treat Rev 1988, 15 (Suppl B), 17-32.
14. Gershenson DM, Kavanagh JJ, Copeland LJ, Stringer CA, Morris M. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol 1989, 73, 798-802.
15. Kjorstad K, Harris A, Bertelsen K, et al. A multicentre phase II study of carboplatin in advanced ovarian carcinoma: final report. Ann Oncol 1992, 3, 217-222.
16. National Cancer Institute PDQ Statement. Ovarian epithelial cancer (PDQ): treatment - health professionals. January 2002.
17. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian neoplasms. Ann Intern Med 1989, 111, 273-279.
18. Kohn EC, Sarosy G, Bicher A, et al. Dose-intensive taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994, 86, 18-24.
19. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum based chemotherapy: a Gynaecologic Oncology Group study. J Clin Oncol 1994, 12, 1748-1753.
20. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumour activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997, 15, 987-993.
21. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001, 19, 3312-3322.
22. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997, 15, 2183-2193.
23. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynaecologic Oncology Group study. J Clin Oncol 1998, 16, 405-410.
24. Bajetta E, Leo AD, Biganzoli L, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum resistant disease. J Clin Oncol 1996, 14, 2546-2551.
25. Gatzemeier U, Twelves C, Anthoney DA, Pentheroudakis G, Groth G, Cosaert J. A phase I dose-escalation study of ZD0473 combined with paclitaxel in refractory solid malignancies. Eur J Cancer 2001, 37, 264 (abstr).
26. Dizon DS, Maluf F, Aghajanian C, et al. Phase I study of ZD0473 and liposomal doxorubicin in advanced refractory solid tumour malignancies. Eur J Cancer 2001, 37, 273 (abstr).